A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients
A Phase 1, Open-Label, Multicenter, Non-Randomized, Dose Escalation Study to Evaluate the Safety and Tolerability of SHR-1316 in Subjects With Advanced Solid Tumors
Sponsor: Atridia Pty Ltd.
Listed as NCT03133247, this PHASE1 trial focuses on Advanced Solid Tumors and remains completed. Sponsored by Atridia Pty Ltd., it has been updated 12 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 7 earlier versions
-
Sep 2019 — Oct 2019 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Aug 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
-
Mar 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
-
Jan 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Jul 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Atridia Pty Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .